National Cancer Institute Home at the National Institutes of Health | www.cancer.gov

Publication Abstract

Authors: Webber EM, Lin JS, Evelyn P Whitlock

Title: Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.

Journal: PLoS Curr 2:-

Date: 2010

Abstract: Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer.

Last Modified: 03 Sep 2013